P2RY12 and migraine disorder: For patients who underwent ASDC, the use of antiplatelet regimens including P2Y12 inhibitors, compared with regimens excluding P2Y12 inhibitors, resulted in a lower rate of new-onset migraine (OR: 0.41, 95% CI: 0.22 to 0.77, P = 0.005) (Figure 4).